Echosens will provide a live demonstration of a FibroScan examination, in partnership with Fidelis, at the Department of Veterans Affairs’ (VA) National Veterans Small Business Engagement
Read More
FAST is a cost-effective tool to help identify individuals at risk for fibrotic NASH, an asymptomatic progressive liver disease that leads to increased liver-related mortality and morbidity.
Echosens joins the American Liver Foundation in observance of Liver Cancer Awareness Month, urging increased awareness of non-alcoholic fatty liver disease (NAFLD) and its more severe form called non-alcoholic steatohepatitis (NASH
Addressing the risk for cirrhosis, liver failure and liver cancer among America’s veterans
Featuring in-depth discussions with physicians and administrators at some of the nation’s leading Federally Qualified Health Centers.
Global Healthcare Business and Technology Expert Leads Company Growth in Chronic Liver Disease Assessment
VA Broadens Contract with Echosens to Include FibroScan mini+ portable Technology, Expands Access to Screening and Early Detection
In this white paper, we explore the growing body of data that show how nonalcoholic fatty liver disease (NAFLD) is becoming recognized as a significant burden to patients, providers, and the overall healthcare system. One study concluded that the costs associated with the care for NAFLD were significantly higher than matched controls with similar metabolic profiles, even before the introduction of pharmacological treatments
Increased Education and Early Detection of Fatty Liver Disease
Highlights Value of Non-Invasive Screening for Fatty Liver Disease
